Linked Life Data

10909319

Source:http://linkedlifedata.com/resource/pubmed/id/10909319

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2000-9-15
pubmed:abstractText
During the past 15 years, the efficacy of antiarrhythmic drugs has been investigated for reducing sudden cardiac death in patients at high risk of arrhythmia. Whereas the benefits of beta-blocker therapy are well established, a reduction in mortality with other antiarrhythmic drugs remains unproved and in some cases, there is evidence of increased mortality with class I and some class III agents. At the same time, the development of the automatic implantable cardioverter-defibrillator has been one of the spectacular achievements in cardiology. It has altered the therapeutic landscape for patients with symptomatic ventricular tachycardia or cardiac arrest. In these patients, the automatic implantable defibrillator is clearly first line therapy, as recognized by the international scientific cardiac societies guidelines.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0370-629X
pubmed:author
pubmed:issnType
Print
pubmed:volume
55
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
307-14
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
[Utilization of implantable ventricular defibrillators (with an analysis of the value of antiarrhythmics in the treatment of potentially fatal ventricular arrhythmias].
pubmed:affiliation
Service de Cardiologie, Université de Liège.
pubmed:publicationType
Journal Article, English Abstract